OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“In the absence of RANK or RANKL, osteoclasts cannot form, function, or survive (62-64, 110, 111).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“RANK and RANKL knockout mice were virtual phenocopies of each other (62)(63)(64), which indicated that RANK and RANKL had few if any roles beyond their mutual interactions.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Another unexpected phenotype found in RANK and RANKL knockout mice was the total lack of lymph nodes (62,64).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Examination of mice genetically deficient in RANKL, RANK, or OPG also revealed no overt dendritic cell defects (62,64,170).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Self-citationManolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z.-Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260
Cited by
Items 201–300 of 1,030
Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3839 · Cited by 318
The Biology of Aseptic Osteolysis
Holt, G., Murnaghan, C., Reilly, J., & Meek, R. M. D. (2007) · Clinical Orthopaedics & Related Research · doi:10.1097/blo.0b013e31804b4147 · Cited by 319
“RANKL also has important roles in the development and regulation of the acquired immune system and is involved in regulating T cell/dendritic cell communications, dendritic cell survival, and lymph node organogenesis.(69,129) Production of RANKL by activated T cells can directly regulate osteoclastogenesis and bone re…”
BackgroundInfluentialHotokezaka, H., Sakai, E., Kanaoka, K., Saito, K., Matsuo, K.-I., Kitaura, H., Yoshida, N., & Nakayama, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208284200 · Cited by 316
Lee, S. E., Woo, K. M., Kim, S. Y., Kim, H.-M., Kwack, K., Lee, Z. H., & Kim, H.-H. (2002) · Bone · doi:10.1016/s8756-3282(01)00657-3 · Cited by 311
Osteoprotegerin, vascular calcification and atherosclerosis
Van Campenhout, A., & Golledge, J. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.033 · Cited by 308
“RANKL expressed n osteoblastic, stromal and T cells binds to RANK on the surface f osteoclasts, monocytic and dendritic cells [13].”
BackgroundLubberts, E., Joosten, L. A. B., Chabaud, M., van den Bersselaar, L., Oppers, B., Coenen-de Roo, C. J. J., Richards, C. D., Miossec, P., & van den Berg, W. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7739 · Cited by 309
“OPGL may play an important role in this differentiation pathway, as OPGL is considered a novel key regulator of osteoclastogenesis (21).”
BackgroundInfluentialLiu, Y.-C. G., Lerner, U. H., & Teng, Y.-T. A. (2010) · Periodontology 2000 · doi:10.1111/j.1600-0757.2009.00321.x · Cited by 306
The genetic transformation of bone biology
Karsenty, G. (1999) · Genes & Development · doi:10.1101/gad.13.23.3037 · Cited by 312
Pancreatic Lymph Node-Derived CD4+CD25+ Treg Cells
Green, E. A., Choi, Y., & Flavell, R. A. (2002) · Immunity · doi:10.1016/s1074-7613(02)00279-0 · Cited by 310
“…T cells correlates with acceler- important for B and T cell development in primary lymphoid organs as well as the development of lymphated diabetes progression in the NOD mouse, a sponta- were fixed in 10% formalin solution (Sigma) prior to embedding innodes and bone resorption (Kong et al., 1999).”
BackgroundHuman Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations
Guerrini, M. M., Sobacchi, C., Cassani, B., Abinun, M., Kilic, S. S., Pangrazio, A., Moratto, D., Mazzolari, E., Clayton-Smith, J., Orchard, P., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.015 · Cited by 309
Noncanonical NF-κB Signaling in Health and Disease
Cildir, G., Low, K. C., & Tergaonkar, V. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.002 · Cited by 301
“RANK and RANKL KO mice exhibit severe osteopetrosis, defective B cell development, and deficiencies in peripheral lymph node generation [31,32].”
Eissner, G., Kolch, W., & Scheurich, P. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.011 · Cited by 298
“Targeted deletion of RANK-L in mice results in reduced osteoclastogenesis and osteopetrosis [25], similar to animals overexpressing OPG [26].”
BackgroundBennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000236428.91125.e6 · Cited by 304
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500704 · Cited by 298
Kim, N., Odgren, P. R., Kim, D.-K., Marks, S. C., & Choi, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200294797 · Cited by 299
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Doherty, T. M., Fitzpatrick, L. A., Inoue, D., Qiao, J.-H., Fishbein, M. C., Detrano, R. C., Shah, P. K., & Rajavashisth, T. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0015 · Cited by 299
“10) RANK, RANKL, and OPG, the decoy receptor for RANKL, are expressed in blood vessels (332–336).”
Pathogenesis of myeloma bone disease
Roodman, G. D. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22403 · Cited by 296
“These animals lack OCLs and develop severe osteopetrosis [Tsukii et al., 1998; Dougall et al., 1999; Kong et al., 1999].”
BackgroundDietary n-3 Fatty Acids Decrease Osteoclastogenesis and Loss of Bone Mass in Ovariectomized Mice
Sun, D., Krishnan, A., Zaman, K., Lawrence, R., Bhattacharya, A., & Fernandes, G. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1206 · Cited by 291
“It is recognized that one of the mechanisms by which estrogen deficiency causes bone loss is stimulation of osteoclast differentiation,((43,44)) a process induced by the stimulation of osteoclast progenitors by macrophage colonystimulating factor (M-CSF) and RANKL simultaneously.((45,46)) In normal physiological condi…”
BackgroundKaden, J. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2003.09.015 · Cited by 285
Crotti, T., Smith, M. D., Hirsch, R., Soukoulis, S., Weedon, H., Capone, M., Ahern, M. J., & Haynes, D. (2003) · Journal of Periodontal Research · doi:10.1034/j.1600-0765.2003.00615.x · Cited by 293
Osteocyte RANKL: New insights into the control of bone remodeling
Xiong, J., & O'Brien, C. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1547 · Cited by 287
“In addition, femurs in mice with germline deletion of RANKL display the Erlenmeyer-flask or club shape that is typical of severe osteopetrosis.((35)) However, femurs in mice lacking RANKL in osteocytes have normal shapes, indicating that modeling of the metaphyseal cortex of long bones is controlled by cells other tha…”
BackgroundRheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy
Alam, J., Jantan, I., & Bukhari, S. N. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.055 · Cited by 280
Angiotensin II accelerates osteoporosis by activating osteoclasts
Shimizu, H., Nakagami, H., Osako, M. K., Hanayama, R., Kunugiza, Y., Kizawa, T., Tomita, T., Yoshikawa, H., Ogihara, T., & Morishita, R. (2008) · The FASEB Journal · doi:10.1096/fj.07-098954 · Cited by 294
“As osteoclast differentiation is regulated by a variety of hormones, local factors, and inflammatory cytokines, such as interleukin-1 and tumor necrosis factor- (26, 27), the renin-angiotensin system is a novel component of the osteoclast differentiation system (Fig.”
BackgroundLocal communication on and within bone controls bone remodeling
Henriksen, K., Neutzsky-Wulff, A. V., Bonewald, L. F., & Karsdal, M. A. (2009) · Bone · doi:10.1016/j.bone.2009.03.671 · Cited by 282
“1A and B), which are essential and sufficient to drive osteoclastogenesis [37–40].”
BackgroundOsteoclast lineage and function
Väänänen, H. K., & Laitala-Leinonen, T. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.037 · Cited by 274
Basis of bone metabolism around dental implants during osseointegration and peri‐implant bone loss
Insua, A., Monje, A., Wang, H., & Miron, R. J. (2017) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36060 · Cited by 277
“Regulation of osteocytes Osteocytes maintain an important role during bone formation and resorption and are the major source of RANKL in bone,(29) required for osteoclast differentiation and function.(31) Osteocytes also function through Wnt signaling pathways and regulate osteoblast proliferation, differentiation, an…”
BackgroundEffects of inflammatory and anti‐inflammatory cytokines on the bone
Schett, G. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02545.x · Cited by 292
Li, X. (2002) · Endocrinology · doi:10.1210/en.143.8.3105 · Cited by 288
Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., & Kostenuik, P. J. (2001) · PubMed · Cited by 318
Self-citationTyrosine kinase receptor RET is a key regulator of Peyer’s Patch organogenesis
Veiga-Fernandes, H., Coles, M. C., Foster, K. E., Patel, A., Williams, A., Natarajan, D., Barlow, A., Pachnis, V., & Kioussis, D. (2007) · Nature · doi:10.1038/nature05597 · Cited by 285
The role of interleukin-1 in the pathogenesis of rheumatoid arthritis
Kay, J. (2004) · Rheumatology · doi:10.1093/rheumatology/keh201 · Cited by 280
“Both cytokines also trigger the differentiation of osteoclasts by stimulating T cells to produce RANK ligand (RANKL), and they both activate mature osteoclasts leading to erosion of subchondral bone [12, 13].”
BackgroundSkeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, A., & Rajawat, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073553 · Cited by 264
Molecular and cellular biology of alveolar bone
SODEK, J., & MCKEE, M. D. (2000) · Periodontology 2000 · doi:10.1034/j.1600-0757.2000.2240106.x · Cited by 283
Functional Biomaterials for Bone Regeneration: A Lesson in Complex Biology
Armiento, A. R., Hatt, L. P., Sanchez Rosenberg, G., Thompson, K., & Stoddart, M. J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909874 · Cited by 273
Bifurcation of osteoclasts and dendritic cells from common progenitors
Miyamoto, T., Ohneda, O., Arai, F., Iwamoto, K., Okada, S., Takagi, K., Anderson, D. M., & Suda, T. (2001) · Blood · doi:10.1182/blood.v98.8.2544 · Cited by 281
The role of cytokines in inflammatory bone loss
Souza, P. P. C., & Lerner, U. H. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.822766 · Cited by 269
“Mice with deletion of Tnfsf11 (encoding RANKL), or of Tnfrsf11a (encoding RANK), exhibit complete lack of osteoclasts and osteopetrosis (Dougall et al., 1999; Kong et al., 1999).”
BackgroundThe Mechanism of Osteoclast Differentiation Induced by IL-1
Kim, J. H., Jin, H. M., Kim, K., Song, I., Youn, B. U., Matsuo, K., & Kim, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803007 · Cited by 270
A Novel Member of the Leukocyte Receptor Complex Regulates Osteoclast Differentiation
Kim, N., Takami, M., Rho, J., Josien, R., & Choi, Y. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011681 · Cited by 273
Transforming Growth Factor β Affects Osteoclast Differentiation via Direct and Indirect Actions
Quinn, J. M. W., Itoh, K., Udagawa, N., Häusler, K., Yasuda, H., Shima, N., Mizuno, A., Higashio, K., Takahashi, N., Suda, T., et al. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1787 · Cited by 278
Influence of sex hormones on the periodontium
Mascarenhas, P., Gapski, R., Al‐Shammari, K., & Wang, H. (2003) · Journal of Clinical Periodontology · doi:10.1034/j.1600-051x.2003.00055.x · Cited by 269
“& Penninger, J. M. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323. Kornman, K. S. & Loesche, W. J. (1980) The subgingival microbial flora during pregnancy. Journal of Periodontal Research 15, 111–122. Kornman, K. S. & Loesche, W. J. (1982)…”
InfluentialSignaling Pathways in Osteoclast Differentiation
Kim, J. H., & Kim, N. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.12 · Cited by 262
“Osteopetrotic bone phenotypes without osteoclasts of both RANKL- and RANK-deficient mice have well revealed that both factors are implicated in regulating osteoclast formation and function.(27,28) Binding of RANKL to RANK leads to recruitment of TNF receptor-associated factor (TRAF) adaptor proteins including TRAFs 1,…”
BackgroundProgesterone signalling in breast cancer: a neglected hormone coming into the limelight
Brisken, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3518 · Cited by 255
Mechanisms of osteolytic bone metastases in breast carcinoma
K�k�nen, S.-M., & Mundy, G. R. (2003) · Cancer · doi:10.1002/cncr.11132 · Cited by 269
“It enhances the differentiation and fusion of active osteoclasts in the presence of macrophage– colony-stimulating factor.(27,28) Concomitantly, the production of a soluble decoy receptor for RANKL, osteoprotegerin, by osteoblastic stromal cells is down-regulated.”
BackgroundBharti, A. C., Takada, Y., & Aggarwal, B. B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.5940 · Cited by 268
Osteoarthritis and osteoporosis: Clinical and research evidence of inverse relationship
Dequeker, J., Aerssens, J., & Luyten, F. P. (2003) · Aging Clinical and Experimental Research · doi:10.1007/bf03327364 · Cited by 269
Inflammatory bone destruction and osteoimmunology
Takayanagi, H. (2005) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2005.00814.x · Cited by 270
Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human
Chalhoub, N., Benachenhou, N., Rajapurohitam, V., Pata, M., Ferron, M., Frattini, A., Villa, A., & Vacher, J. (2003) · Nature Medicine · doi:10.1038/nm842 · Cited by 271
Weitzmann, M. N. (2013) · Scientifica · doi:10.1155/2013/125705 · Cited by 259
Ruddle, N. H., & Akirav, E. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804324 · Cited by 259
Regulation of Peripheral Lymph Node Genesis by the Tumor Necrosis Factor Family Member Trance
Kim, D., Mebius, R. E., MacMicking, J. D., Jung, S., Cupedo, T., Castellanos, Y., Rho, J., Wong, B. R., Josien, R., Kim, N., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.10.1467 · Cited by 264
Kovacs, C. S. (2014) · Physiological Reviews · doi:10.1152/physrev.00014.2014 · Cited by 258
“Deletion of RANKL results in osteopetrotic changes in mice by 2 days after birth, whereas growth and serum calcium, phosphorus, and alkaline phosphatase remain normal until weaning (322).”
BackgroundDenosumab treatment for fibrous dysplasia
Boyce, A. M., Chong, W. H., Yao, J., Gafni, R. I., Kelly, M. H., Chamberlain, C. E., Bassim, C., Cherman, N., Ellsworth, M., Kasa-Vubu, J. Z., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1603 · Cited by 260
“Preclinical studies with denosumab in rodents and primates demonstrated a significant inhibitory effect on linear growth and tooth eruption.((38,39)) In our patient there was no increase in arm span over a 6-month period, which may represent impaired linear growth as a complication of treatment.”
BackgroundRoles of Mitogen-Activated Protein Kinases in Osteoclast Biology
Lee, K., Seo, I., Choi, M. H., & Jeong, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103004 · Cited by 251
“RANKL/RANK/TRAF6/ERK cascades have been shown to regulate osteoclast formation and function [22,23].”
BackgroundAkt Induces Osteoclast Differentiation through Regulating the GSK3β/NFATc1 Signaling Cascade
Moon, J. B., Kim, J. H., Kim, K., Youn, B. U., Ko, A., Lee, S. Y., & Kim, N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101254 · Cited by 252
Kikuchi, T., Matsuguchi, T., Tsuboi, N., Mitani, A., Tanaka, S., Matsuoka, M., Yamamoto, G., Hishikawa, T., Noguchi, T., & Yoshikai, Y. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3574 · Cited by 255
“ODF-deficient mice have recently been generated (12).”
Huang, L., Xu, J., Wood, D. J., & Zheng, M. H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64942-5 · Cited by 260
“7 It has been assumed that OPGL acts as an osteoclastogenesis-inducing factor linked to interaction between stromal cells and osteoclast progenitors.”
BackgroundMethodInfluentialAliahmad, P., de la Torre, B., & Kaye, J. (2010) · Nature Immunology · doi:10.1038/ni.1930 · Cited by 243
“These include earlier embryonic development and reliance on TRANCE signaling for the latte”
BackgroundStromal Cells in Chronic Inflammation and Tertiary Lymphoid Organ Formation
Buckley, C. D., Barone, F., Nayar, S., Bénézech, C., & Caamaño, J. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120252 · Cited by 249
Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr (−/−) Mice
Morony, S., Tintut, Y., Zhang, Z., Cattley, R. C., Van, G., Dwyer, D., Stolina, M., Kostenuik, P. J., & Demer, L. L. (2008) · Circulation · doi:10.1161/circulationaha.107.707380 · Cited by 258
Self-citationDiscovery of the RANKL/RANK/OPG system
Yasuda, H. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01175-1 · Cited by 234
“As mentioned above, RANKL-KO mice exhibit osteopetrosis with no osteoclasts [18].”
BackgroundResultOctacalcium phosphate: Osteoconductivity and crystal chemistry
Suzuki, O. (2010) · Acta Biomaterialia · doi:10.1016/j.actbio.2010.04.002 · Cited by 252
Onal, M., Xiong, J., Chen, X., Thostenson, J. D., Almeida, M., Manolagas, S. C., & O'Brien, C. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377945 · Cited by 249
“Previous studies have shown that germ-line deletion of RANKL also leads to an 50% reduction in the percentage of CD45R/B220 IgM B cells in the spleen (11).”
BackgroundResultInfluentialChai, Q., Onder, L., Scandella, E., Gil-Cruz, C., Perez-Shibayama, C., Cupovic, J., Danuser, R., Sparwasser, T., Luther, S. A., Thiel, V., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.012 · Cited by 249
“, 2007) andmolecules of the tumor necrosis factor (TNF) family expressed by LTi cells provide essential signals for the developing SLOs (De Togni et al., 1994; Koni et al., 1997; Kong et al., 1999).”
BackgroundUpdating osteoimmunology: regulation of bone cells by innate and adaptive immunity
Walsh, M. C., Takegahara, N., Kim, H., & Choi, Y. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.213 · Cited by 252
Tumor Necrosis Factor-α Supports the Survival of Osteoclasts through the Activation of Akt and ERK
Lee, S. E., Chung, W. J., Kwak, H. B., Chung, C.-H., Kwack, K., Lee, Z. H., & Kim, H.-H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103642200 · Cited by 254
The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity
Müller, G., Höpken, U. E., & Lipp, M. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00073.x · Cited by 251
Armstrong, A. P., Tometsko, M. E., Glaccum, M., Sutherland, C. L., Cosman, D., & Dougall, W. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202009200 · Cited by 249
Mechanism of alveolar bone destruction in periodontitis — Periodontal bacteria and inflammation
Usui, M., Onizuka, S., Sato, T., Kokabu, S., Ariyoshi, W., & Nakashima, K. (2021) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2021.09.005 · Cited by 223
“Osteoclast did not form in mice lacking the RANKL gene or patients with mutations in the RANKL gene, resulting in osteopetrosis with increased bone mass, indicating that RANKL is an essential factor for osteoclastogenesis [11,12].”
BackgroundRuocco, M. G., Maeda, S., Park, J. M., Lawrence, T., Hsu, L.-C., Cao, Y., Schett, G., Wagner, E. F., & Karin, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042081 · Cited by 252
“RANKL (also called tumor necrosis factor– related activation-induced cytokine, osteoclast differentiation factor, osteoprotegerin ligand) is a member of the TNF cytokine family and an essential inducer of osteoclastogenesis and bone remodeling through its receptor RANK, a TNF-receptor (TNFR) family member (5, 6).”
BackgroundOsteocyte control of osteoclastogenesis
O'Brien, C. A., Nakashima, T., & Takayanagi, H. (2013) · Bone · doi:10.1016/j.bone.2012.08.121 · Cited by 235
“Regardless of the identity of the cell types that support osteoclast differentiation, such cells do so by expressing the cytokine receptor activator of NFκB ligand (RANKL), which is essential for osteoclast differentiation, function, and survival [1].”
BackgroundEstrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells
Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251
Organizer-Like Reticular Stromal Cell Layer Common to Adult Secondary Lymphoid Organs
Katakai, T., Suto, H., Sugai, M., Gonda, H., Togawa, A., Suematsu, S., Ebisuno, Y., Katagiri, K., Kinashi, T., & Shimizu, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6189 · Cited by 242
“TNF-related activation-induced cytokine (TRANCE), a key factor in osteoclastogenesis, participates in the proliferation and differentiation of LTi cells, particularly in the LN anlagen (23); hence, all LNs but not all PPs are absent in mice deficient in TRANCE or its receptor TRANCE-R (24, 25).”
BackgroundItoh, K., Udagawa, N., Katagiri, T., Iemura, S., Ueno, N., Yasuda, H., Higashio, K., Quinn, J. M. W., Gillespie, M. T., Martin, T. J., et al. (2001) · Endocrinology · doi:10.1210/endo.142.8.8300 · Cited by 250
Takeshita, S., Namba, N., Zhao, J. J., Jiang, Y., Genant, H. K., Silva, M. J., Brodt, M. D., Helgason, C. D., Kalesnikoff, J., Rauh, M. J., et al. (2002) · Nature Medicine · doi:10.1038/nm752 · Cited by 252
“Although macrophage number is normal, RANKL-deficient mice are osteopetrotic due to the complete absence of OCs (ref”
BackgroundQiang, Y.-W., Chen, Y., Stephens, O., Brown, N., Chen, B., Epstein, J., Barlogie, B., & Shaughnessy, J. D. (2008) · Blood · doi:10.1182/blood-2008-01-132134 · Cited by 248
“The evidence supporting this model are the following: (1) DKK1 inhibits Wnt3a-induced stabilization of -catenin and reduces free- -catenin in both mouse and human osteoblast cells, (2) exogenous administration of DKK1 or constitutive expression of DKK1 dramatically diminished Wnt3a induced OPG expression in osteoblast…”
ResultMansky, K. C., Sankar, U., Han, J., & Ostrowski, M. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111696200 · Cited by 243
IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast Formation In Vitro
Horwood, N. J., Elliott, J., Martin, T. J., & Gillespie, M. T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4915 · Cited by 251
“A similar phenotype is also noted in the RANKL-deficient mice (4).”
BackgroundMebius, R. E., Miyamoto, T., Christensen, J., Domen, J., Cupedo, T., Weissman, I. L., & Akashi, K. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6593 · Cited by 242
The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
Hashizume, M., & Mihara, M. (2011) · Arthritis · doi:10.1155/2011/765624 · Cited by 238
Hirotani, H., Tuohy, N. A., Woo, J.-T., Stern, P. H., & Clipstone, N. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m213067200 · Cited by 246
Danks, L., Komatsu, N., Guerrini, M. M., Sawa, S., Armaka, M., Kollias, G., Nakashima, T., & Takayanagi, H. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207137 · Cited by 240
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246
“Inhibition of T and B cell function has been observed in RANKL-deficient mice (100).”
BackgroundVascular calcification and osteoporosis—from clinical observation towards molecular understanding
Hofbauer, L. C., Brueck, C. C., Shanahan, C. M., Schoppet, M., & Dobnig, H. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0282-z · Cited by 248
“By contrast, mice carrying an OPG transgene or mice treated with an OPG fusion protein [59] or RANKL knockout mice [60] have no or fewer osteoclasts and develop osteopetrosis with hepatosplenomegaly due to extramedullary hematopoiesis.”
BackgroundRANKL Expression Is Related to the Differentiation State of Human Osteoblasts
Atkins, G. J., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., Harrison, K., Findlay, D. M., & Zannettino, A. C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1088 · Cited by 245
“Deletion of the RANKL gene in mice resulted in severe osteopetrosis and a complete lack of osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis.((17)) The soluble TNF-receptor family member, osteoprotegerin (OPG), is a natural RANKL antagonist, which can inhibit osteoclast formation and…”
BackgroundCentral control of fever and female body temperature by RANKL/RANK
Hanada, R., Leibbrandt, A., Hanada, T., Kitaoka, S., Furuyashiki, T., Fujihara, H., Trichereau, J., Paolino, M., Qadri, F., Plehm, R., et al. (2009) · Nature · doi:10.1038/nature08596 · Cited by 238
Self-citationPathogenesis of bone erosions in rheumatoid arthritis
Goldring, S. R., & Gravallese, E. M. (2000) · Current Opinion in Rheumatology · doi:10.1097/00002281-200005000-00006 · Cited by 249
Advances in osteoclast biology: old findings and new insights from mouse models
Edwards, J. R., & Mundy, G. R. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.23 · Cited by 235
“Transgenic mice that overexpress a soluble RANK fusion protein have a severely osteopetrotic phenotype similar to that of OPG-transgenic mice (these animals overexpress OPG)”
BackgroundConnection Between B Lymphocyte and Osteoclast Differentiation Pathways
Manabe, N., Kawaguchi, H., Chikuda, H., Miyaura, C., Inada, M., Nagai, R., Nabeshima, Y.-I., Nakamura, K., Sinclair, A. M., Scheuermann, R. H., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2625 · Cited by 240
B Cell Development and Maturation
Wang, Y., Liu, J., Burrows, P. D., & Wang, J.-Y. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3532-1_1 · Cited by 210
Myeloma bone disease: pathophysiology and management
Terpos, E., & Dimopoulos, M.-A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi235 · Cited by 235
“Mice that lack either RANKL or RANK or that over-express OPG develop osteopetrosis because of decreased osteoclast activity [20].”
BackgroundOsteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow
Mansour, A., Abou-Ezzi, G., Sitnicka, E., W. Jacobsen, S. E., Wakkach, A., & Blin-Wakkach, C. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20110994 · Cited by 216
“…severe osteopetrosis, whch is associated with extramedullary hematopoiesis, suggesting that OCLs may participate not only in the regulation or maintenance but also in the initial formation of the HSC niche (Dougall et al., 1999; Kong et al., 1999; Tagaya et al., 2000; Blin-Wakkach et al., 2004b).”
BackgroundCao, J. J., Gregoire, B. R., & Gao, H. (2009) · Bone · doi:10.1016/j.bone.2009.02.017 · Cited by 235
“To further elucidate the possible mechanism by which HFD affects bone structure and cell functions, we measured serum TRAP concentration and mRNA levels of RANKL, OPG and M-CSF in cultured osteoblasts [46–48].”
BackgroundOsteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity
Venuraju, S. M., Yerramasu, A., Corder, R., & Lahiri, A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.013 · Cited by 237
“RANKL is expressed in vivo by osteoblasts, stromal cells, nd T lymphocytes (18).”
BackgroundOsteoclast precursors, RANKL/RANK, and immunology
Xing, L., Schwarz, E. M., & Boyce, B. F. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00336.x · Cited by 231
“Differentiation of CD11b+/Gr1–/lo/c-Fms+ late stage OCPs from CD11b+/Gr-1–/lo/c-Fms– early stage progenitors involves differentiation, proliferation, and anti-apoptotic signals, which are provided by M-CSF produced by osteoblast/bone marrow stromal cells through its receptor, c-Fms. c-Fms–/– mice have no tartrate-resi…”
BackgroundInfluentialHenriksen, K., Bollerslev, J., Everts, V., & Karsdal, M. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0006 · Cited by 230
Effects of growth factors and cytokines on osteoblast differentiation
Hughes, F. J., Turner, W., Belibasakis, G., & Martuscelli, G. (2006) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00161.x · Cited by 233
Hikita, A., Yana, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura, K., Seiki, M., & Tanaka, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606656200 · Cited by 236
Bone remodeling in rheumatic disease: a question of balance
Walsh, N. C., & Gravallese, E. M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00857.x · Cited by 230
“Not only are osteoblasts responsible for adequate bone formation, but they also modulate osteoclast differentiation and function through the production of the essential osteoclast differentiation factor, RANKL (45), and its decoy receptor OPG.”
BackgroundRANK‐mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis
Gohda, J., Akiyama, T., Koga, T., Takayanagi, H., Tanaka, S., & Inoue, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600564 · Cited by 226
“RANKL- or RANK-deficient mice display osteope- trosis due to a lack of osteoclasts (Dougall et al, 1999; Kong et al, 1999).”
BackgroundIn vitro models for the study of osteoarthritis
Johnson, C. I., Argyle, D. J., & Clements, D. N. (2016) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.07.011 · Cited by 220
“279 Further, generation of RANKL is induced by IL-6 and IL-1, and mice lacking RANKL 280 completely lack osteoclasts (Kong et al., 1999).”
Background
Metadata
- Authors
- Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., & Penninger, J. M.
- Affiliations
- University of Toronto (CA)
- Amgen (United States) (US)
- Corresponding author
- Penninger, Josef M.
- Venue
- Nature
- Published
- 1999-01
- Volume
- 397
- Issue
- 6717
- Pages
- 315-323
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1534645474
- Cited by
- 3,351
- References
- 52
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 58 · 2023: 71 · 2022: 88 · 2021: 114 · 2020: 121 · 2019: 102 · 2018: 95 · 2017: 115 · 2016: 107 · 2015: 125 · 2014: 119 · 2013: 138 · 2012: 162
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- osteoprotegerin ligand, RANKL, osteoclastogenesis, osteopetrosis, tooth eruption, lymphocyte development, dendritic cells, T cell development, B cell development, osteoblasts
- MeSH terms
- Animals, B-Lymphocytes, Carrier Proteins, Cell Differentiation, Cells, Cultured, Dendritic Cells, Female, Embryonic and Fetal Development, Growth Substances, Hematopoiesis, Extramedullary, Hematopoietic Stem Cells, Lymph Nodes, Lymphocyte Activation, Lymphocytes, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Osteoclasts, Osteogenesis, Osteopetrosis, T-Lymphocytes, Thymus Gland, Cytokines, Mutagenesis, Bone Remodeling, Gene Targeting, Leukopoiesis, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.